CLLS Cellectis SA

(Article 223-16 of General Regulation of the French financial markets authority)

Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS):

Listing market: NYSE Euronext Paris

ISIN code: FR0010425595

Date   Total number of shares

in the capital

  Total number of voting rights 08/31/2017   35,415,473   40,705,002

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170907006654/en/

CellectisMedia:Jennifer Moore, 917-580-1088VP of Communicationsmedia@cellectis.comorCaitlin Kasunich, 212-896-1241KCSA Strategic Communicationsckasunich@kcsa.comIR:Simon Harnest, 646-385-9008VP of Corporate Strategy and Financesimon.harnest@cellectis.com